Daniel Shu
机构: University of Maryland, Baltimore
每年引用次数
引用次数
引用: 167
H-指数: 5
I10-指数 : 4
出版物: 23
Prion-like Aggregation of Mitochondrial Antiviral Signaling Protein in Lupus Patients Is Associated With Increased Levels of Type I Interferon.
Wen-Hai Shao , Daniel H. Shu , Yuxuan Zhen , Brendan Hilliard
Arthritis & Rheumatism 68 ( 11) 2697 -2707
29
2016
Aggregation of MAVS antiviral protein suggests a mechanism for increased type I interferon production in SLE
Wen-Hai Shao , Brendan A Hilliard , Daniel H Shu , Stephen O Priest
Arthritis Research & Therapy 16 ( 1) 1 -23
1
2014
Transformation of metastatic nonfunctioning pancreatic neuroendocrine tumor into insulinoma—two case reports
Lawrence W Wu , Syed M Qasim Hussaini , Jae W Lee , Daniel H Shu
Annals of Pancreatic Cancer 5
1
2022
Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockade
Daniel H Shu , Won Jin Ho , Luciane T Kagohara , Alexander Girgis
bioRxiv
3
2023
12-chemokine gene signature identifies major pathologic response in patients with hepatocellular carcinoma treated with neoadjuvant nivolumab and cabozantinib
Daniel H Shu , Ludmila Danilova , Long Yuan , Qingfeng Zhu
Cancer Research 82 ( 12_Supplement) 1323 -1323
2
2022
Machine learning integrating spatial omics uncovers humoral immunity patterns in intratumoral tertiary lymphoid structures in pancreatic cancer pathologic responders
Dimitrios N Sidiropoulos , Sarah M Shin , Alexander Girgis , Daniel H Shu
Cancer Research 84 ( 6_Supplement) 1159 -1159
2024
Identification of a novel morphology of tertiary lymphoid structure in patients with hepatocellular carcinoma treated with neoadjuvant immune checkpoint blockade
Daniel H Shu , Won Jin Ho , Luciane T Kagohara , Alexander Girgis
Cancer Research 84 ( 6_Supplement) 2661 -2661
2024
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial
Mark Yarchoan , Edward J Gane , Thomas U Marron , Renzo Perales-Linares
Nature medicine 1 -10
3
2024
PERSONALIZED NEOANTIGEN DNA VACCINE (GNOS-PV02) AND PEMBROLIZUMAB AS SECOND-LINE TREATMENT FOR ADVANCED HEPATOCELLULAR CARCINOMA
Mark Yarchoan , Edward J Gane , Thomas U Marron , Renzo Perales-Linares
Dermatitis 1 2.8 -2.8
2024
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
Antonio D'Alessio , Bernardo Stefanini , Julia Blanter , Benjamin Adegbite
The Lancet Oncology
2024
Maturation of tertiary lymphoid structures
Daniel H Shu , Dimitrios N Sidiropoulos
Tertiary Lymphoid Structures: Methods and Protocols 43 -55
1
2024
209 Spatial multi-omics reveal humoral immunity niches associated with tertiary lymphoid structures in pancreatic cancer pathologic responders to neoadjuvant immunotherapy
Dimitrios N Sidiropoulos , Sarah M Shin , Alexander Girgis , Meredith Wetzel
Journal for ImmunoTherapy of Cancer 12 ( Suppl 2)
2024
Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma
Daniel H Shu , Won Jin Ho , Luciane T Kagohara , Alexander Girgis
Nature Immunology 1 -14
2024
Abstract PR-08: Reprogramming and selective recruitment of distinct neutrophil subpopulations restrain cancer metastasis
Jae W Lee , Diana Caroline Vargas Carvajal , Yeonju Cho , Sarah M Shin
Cancer Research 84 ( 17_Supplement_2) PR -PR
2024
Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancreatic cancer immunotherapy pathologic responders
Dimitrios N Sidiropoulos , Sarah M Shin , Meredith Wetzel , Alexander A Girgis
bioRxiv 2024.09. 22.613714 -2024.09. 22.613714
2024
104 SLE autoantibodies to casein kinase II: potential mediators of immunopathology
Daniel H Shu , Joan T Merrill , Philip L Cohen
Lupus Science & Medicine 9 ( Suppl 3)
2022
miR-21 as a post-transcriptional regulator of pancreatic ductal adenocarcinoma (PDAC) tumorigenesis
Jacquelyn W Zimmerman , Daniel H Shu , Richard A Burkhart , Joseph Tandurella
Cancer Research 82 ( 12_Supplement) 1480 -1480
2022
Qualification of major pathological response as a surrogate endpoint for relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma.
Antonio D'Alessio , Bernardo Stefanini , Julia Blanter , Benjamin Adegbite
Journal of Clinical Oncology 42 ( 3_suppl) 506 -506
1
2024
Spatial transcriptomics of advanced hepatocellular carcinomas distinguishes intercellular interactions in responders and non-responders to cabozantinib and nivolumab neoadjuvant therapy
Luciane T Kagohara , Shuming Zhang , Long Yuan , Qingfeng Zhu
Cancer Research 82 ( 12_Supplement) 3820 -3820
2022
Salvage ipilimumab plus nivolumab after anti-PD-1/PD-L1 therapy in advanced hepatocellular carcinoma
Stephanie L Alden , Mir Lim , Chester Kao , Daniel Shu
Cancer Research Communications 3 ( 7) 1312 -1317
8
2023